DOCSLIB.ORG

2-The Putative Neurodegenerative Links.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2-The Putative Neurodegenerative Links.Pdf Progress in Neurobiology 91 (2010) 362–375 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio The putative neurodegenerative links between depression and Alzheimer’s disease Suthicha Wuwongse a,b, Raymond Chuen-Chung Chang b,c,d,*, Andrew C.K. Law a,c,d,** a Department of Psychiatry, LKS Faculty of Medicine, Hong Kong b Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, Hong Kong c Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, Hong Kong d State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong ARTICLE INFO ABSTRACT Article history: Alzheimer’s disease (AD) is the leading neurodegenerative cause of dementia in the elderly. Thus far, Received 11 September 2009 there is no curative treatment for this devastating condition, thereby creating significant social and Received in revised form 16 April 2010 medical burdens. AD is characterized by progressive cognitive decline along with various Accepted 27 April 2010 neuropsychiatric symptoms, including depression and psychosis. Depression is a common psychiatric disorder affecting individuals across the life span. Although the Keywords: ‘‘monoamine hypothesis’’ of depression has long been proposed, the pathologies and mechanisms for Alzheimer’s disease depressive disorders remain only partially understood. Pharmacotherapies targeting the monoaminer- Depression gic pathways have been the mainstay in treating depression. Additional therapeutic approaches focusing Neuroinflammation Brain-derived nerve growth factor other pathological mechanisms of depression are currently being explored. Neurodegeneration Interestingly, a number of proposed mechanisms for depression appear to be similar to those Cortisol implicated in neurodegenerative diseases, including AD. For example, diminishing neurotrophic factors and neuroinflammation observed in depression are found to be associated with the development of AD. This article first provides a concise review of AD and depression, then discusses the putative links between the two neuropsychiatric conditions. ß 2010 Elsevier Ltd. All rights reserved. Contents 1. Alzheimer’s disease . 363 1.1. Clinical and pathological features of AD . 363 1.1.1. Pathogenic factors for AD . 363 1.1.2. From cholinergic neurons to glutamatergic neurons in AD . 364 1.1.3. Neurodegenerative processes in AD . 364 1.2. Treatment of AD . 364 1.2.1. Current available treatments. 365 1.2.2. Therapeutic research directions . 365 Abbreviations: 5HTT, serotonin transporter; Ab, amyloid beta; ACh, acetylcholine; AChE-I, acetylcholinesterase inhibitor; ACTH, adrenocorticotropic hormone; AD, Alzheimer’s disease; AMPA, a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate; APP, amyloid precursor protein; BACE1, b-site APP cleaving enzyme; BDNF, brain derived neurotrophic factor; BuChE, butyrylcholinesterase; CREB, cAMP response element binding protein; CRH, corticotropin releasing hormone; GSK-3b, glycogen synthase kinase-3 beta; HPA, hypothalamus-pituitary-adrenal; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFNg, interferon gamma; IFNa, interferon alpha; IL-1b, interleukin 1 beta; IL-6, interleukin 6; MAO-A, monoamine oxidase A; MAO-B, monoamine oxidase B; MAOI, monoamine oxidase inhibitor; MAPK, mitogen activated protein kinase; MDD, major depressive disorder; NFT, neurofibrillary tangles; NGF, nerve growth factor; NMDA, N-methyl-D-aspartic acid; NFkB, nuclear factor kappa-light-chain- enhancer of activated B cells; PD, Parkinson’s disease; PS1, presenilin 1; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TLR, toll-like receptor; TNFa, tumor necrosis factor alpha; TGFb, transforming growth factor beta. * Corresponding author at: Department of Anatomy, The University of Hong Kong, Rm. L1-49, Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong. Tel.: +852 2819 9127; fax: +852 2817 0857. ** Corresponding author at: Department of Psychiatry, The University of Hong Kong, Room 219, Block J, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong. Fax: +852 2819 3851. E-mail addresses: [email protected] (R.-C. Chang), [email protected] (Andrew C.K. Law). 0301-0082/$ – see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.pneurobio.2010.04.005 S. Wuwongse et al. / Progress in Neurobiology 91 (2010) 362–375 363 2. Depression . 365 2.1. Clinical and pathological features of depression . 365 2.1.1. HPA axis dysregulation . 366 2.1.2. Dysregulation of monoaminergic neurotransmitters . 366 2.1.3. Involvement of inflammation and neurotrophic factor deficiency in depression . 366 2.2. Antidepressants. 367 2.2.1. Existing depression pharmacotherapy . 367 2.2.2. Antidepressant research directions. 367 3. Depression and Alzheimer’s disease . 367 3.1. Epidemiological observations . 367 3.2. Genetic studies . 367 3.3. Pathological and biochemical linkage . 369 3.4. Clinical investigation . 370 4. Summary....................................................................................................... 371 Acknowledgements . 371 References...................................................................................................... 371 1. Alzheimer’s disease Ab plaques and NFT are the most prominent histological features in the AD brain. NFT are positively associated with clinical Alzheimer’s disease (AD) is the most common neurodegenerative severity in AD patients, estimated by the Clinical Dementia Rating form of dementia. Aging is the most important risk factor for AD. The and Mini-Mental State Examination scores (Giannakopoulos et al., prevalence of AD is approximately 7–10% in individuals over the age 2003; Gold et al., 2001). On the other hand, studies regarding the of 65 and increases to about 40% over the age of 80. AD is incurable clinical correlations of Ab plaques are equivocal (Gold et al., 2001). and increases the mortality rate by approximately 40% in men and Ab and NFT trigger a number of mechanisms leading to neuronal women. The number of people who have AD is expected to double death. Altered cholinergic and glutamatergic neurotransmission, every 20 years, thereby constituting significant medio- and socio- apoptosis, oxidative stress, calcium homeostasis dysfunction, and economical burdens (Alzheimer’s Association, 2009). neuroinflammation are some of the proposed mechanisms Several genetic risk factors have been identified in AD. implicated in the AD pathogenesis. Mutations in the amyloid precursor protein (APP) gene on chromosome 21, presenilin 1 (PS1) on chromosome 14, and 1.1.1. Pathogenic factors for AD presenilin 2 on chromosome 1 have been found to be responsible Ab is believed to play a central role in the pathogenesis of AD. for the early-onset, autosomal dominant forms of AD (Levy-Lahad Extracellular Ab plaques found in AD brains are surrounded by et al., 1995; St George-Hyslop et al., 1987; Van Broeckhoven et al., dystrophic dendrites and axons, activated microglia, and reactive 1992). Alternatively, the epsilon 4 variant of apolipoprotein E gene astrocytes (Gomez-Isla et al., 2008). located on chromosome 19 has been found to be involved in the Ab is an abnormal by-product of the cleavage of APP. APP is a late-onset, sporadic form of the disease (Utermann, 1994). These transmembrane protein having roles in neuronal protection and genetic factors influence the pathology of AD by enhancing the development (Turner et al., 2003). APP is cleaved by a, b,andg- accumulation and aggregation of amyloid b (Ab) and neurofibril- secretases. APP can undergo two cleavage pathways: amyloido- lary tangles (NFT) (Selkoe, 2001; Williamson et al., 2009). Other genic and non-amyloidogenic, depending on the cleaving important candidate genes include death associated protein kinase enzymes involved. When APP is cleaved by a-secretase followed 1—an enzyme involved in neuronal apoptosis; insulin-degrading by g-secretase, the possibility of Ab formation is eliminated, as enzyme gene responsible for producing insulin degrading enzyme, a-secretase mediated cleavage occurs within the Ab region which is involved in the degradation and clearance of Ab; and (Sisodia, 1992). Under the ‘‘amyloidogenic’’ condition, APP is growth factor receptor-bound 2 associated binding protein, which first cleaved by b-secretase followed by the g-secretase was found to be overexpressed in pathologically vulnerable cleavage, thereby releasing the neurotoxic 40 to 42 amino acid neurons and its expression increases tau hyperphosphorylation peptidic fragments. b-site APP cleaving enzyme 1 (BACE1) and (Bertram et al., 2000; Li et al., 2006; Reiman et al., 2007). More presenilins have been suggested to be the major constituents of recently, the neuronal sortilin-related receptor gene on chromo- b-andg-secretases, respectively (Hampel and Shen, 2009; some 11, has been shown in several studies to be associated with Thinakaran et al., 1996; Vassar, 2004). Recent studies show that AD (Rogaeva et al., 2007; Webster et al., 2008). oligomeric Ab are also neurotoxic. These findings suggest that Ab-mediated neurotoxicity could be an early pathological event 1.1. Clinical and pathological features of AD leading to neuronal demise in AD (Pereira et al., 2005; Schott et al., 2006). The primary clinical presentation of AD is progressive cognitive Intraneuronal NFT are composed of hyperphosphorylated tau decline, with memory loss being a relatively early sign of the proteins
Load more

Recommended publications
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • Clinical Review Huntington's Disease
    CLINICAL REVIEW For the full versions of these articles see bmj.com Huntington’s disease Marianne J U Novak,1 2 Sarah J Tabrizi1 3 1National Hospital for Neurology Huntington’s disease is a devastating inherited and Neurosurgery, London neurodegenerative disease characterised by progressive motor, WC1N 3BG cognitive, and psychiatric symptoms. Patients may present 2Wellcome Trust Centre for Neuroimaging, UCL Institute of with any of these symptoms, and familiarity with the pheno- Neurology, London WC1N 3BG type is therefore important. Chorea and loss of balance are 3Department of Neurodegenerative early symptoms that patients notice, although families often Disease, UCL Institute of Neurology notice cognitive or personality changes before this. Correspondence to: S Tabrizi [email protected] The disease occurs in all racial groups but is most common in people of northern European origin. Its prevalence in the Cite this as: BMJ 2010;340:c3109 Western hemisphere is 7-10/100 000.w1 The mean age of onset doi: 10.1136/bmj.c3109 of symptoms is 40 years, but juvenile onset (<20 years) and older onset (>70 years) forms are well recognised. The Hunt- ington’s Disease Association (HDA) has records of 6161 adults with symptomatic Huntington’s disease and 541 children with juvenile Huntington’s disease (in England and Wales) at the Fig 1 | Statistical parametric map showing grey matter volume loss in patient groups compared with controls. Pre-A and time of writing. This is a conservative estimate of prevalence pre-B are premanifest Huntington’s disease gene carriers with because it includes only those people in contact with the HDA, estimated time to clinical disease onset greater than and less and it suggests that the true prevalence of the disease is higher than 10.8 years, respectively.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Serotonergic System Antagonists Target Breast Tumor Initiating Cells and Synergize with Chemotherapy to Shrink Human Breast Tumor Xenografts
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 19), pp: 32101-32116 Research Paper Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts William D. Gwynne1, Robin M. Hallett1, Adele Girgis-Gabardo1, Bojana Bojovic1, Anna Dvorkin-Gheva2, Craig Aarts1, Kay Dias2, Anita Bane2 and John A. Hassell1,2 1Department of Biochemistry and Biomedical Sciences, McMaster University, Canada 2Department of Pathology and Molecular Medicine, McMaster University, Canada Correspondence to: John A. Hassell, email: [email protected] Keywords: breast cancer stem cells, tumor-initiating cells, serotonin antagonists, antidepressants, cytotoxic chemotherapy Received: November 25, 2016 Accepted: March 01, 2017 Published: March 29, 2017 Copyright: Gwynne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Breast tumors comprise an infrequent tumor cell population, termed breast tumor initiating cells (BTIC), which sustain tumor growth, seed metastases and resist cytotoxic therapies. Hence therapies are needed to target BTIC to provide more durable breast cancer remissions than are currently achieved. We previously reported that serotonergic system antagonists abrogated the activity of mouse BTIC resident in the mammary tumors of a HER2-overexpressing model
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Démence, Suivies Par La Fiche De Transparence De Juillet 2008
    Cette version online contient toutes les mises à jour disponibles au sujet de la prise en charge médicamenteuse de la démence, suivies par la Fiche de transparence de juillet 2008. Démence Date de recherche jusqu’au 15 septembre 2015 Épidémiologie Les résultats d’une étude cas-témoins canadienne menée auprès d’environ 1.800 personnes âgées suggèrent que l’usage prolongé (3 mois ou plus) de benzodiazépines constitue un facteur de risque pour le développement de la maladie d’Alzheimer. Ce type d’étude ne permet toutefois pas d’établir un lien causal : en effet, les benzodiazépines sont souvent prescrites en cas d’insomnie ou d’anxiété, qui peuvent être les symptômes précurseurs d’un syndrome démentiel a, 1, 2. Par ailleurs, les auteurs n’ont pas étudié le lien avec les médicaments psychotropes autres que les benzodiazépines, ce qui est nécessaire pour pouvoir déterminer si l’association constatée est spécifique aux benzodiazépines 3. En tout cas, les benzodiazépines ont un effet négatif sur la mémoire, et chez les personnes âgées, il convient de rester prudent et d’évaluer attentivement le rapport bénéfice/risque 4. a. Des personnes âgées (> 66 ans, n = 1.796) ayant reçu pour la première fois le diagnostic de la maladie d’Alzheimer après une période de suivi d’au moins 6 ans, ont été comparées à un groupe témoin (n = 7.184) apparié en âge, sexe et durée de suivi. La prise de benzodiazépines doit avoir commencée au moins 5 ans auparavant, afin de diminuer le risque d’un lien causal inverse. Dans l’analyse, on a tenu compte de la dose quotidienne cumulative et de la demi-vie.
    [Show full text]
  • A Physician's Guide to the Management of Huntington's Disease
    A Physician’s Guide to the Management of Huntington’s Disease Third Edition Martha Nance, M.D. Jane S. Paulsen, Ph.D. Adam Rosenblatt, M.D. Vicki Wheelock, M.D. Front Cover Image: Volumetric 3 Tesla MRI scan from an individual carrying the HD mutation, with full manifestation of the disease. The scan shows atrophy of the caudate. Acknowledgements: Images were acquired as part of the TRACK-HD study of which Professor Sarah Tabrizi is the Principal Investigator. TRACK-HD is funded by CHDI Foundation, Inc., a not-for-profit organization dedicated to funding treatments for Huntington¹s disease. A Physician’s Guide to the Management of Huntington’s Disease Third Edition Martha Nance, M.D. Director, HDSA Center of Excellence at Hennepin County Medical Center Medical Director, Struthers Parkinson’s Center, Minneapolis, MN Adjunct Professor, Department of Neurology, University of Minnesota Jane S. Paulsen, Ph.D. Director HDSA Center of Excellence at the University of Iowa Professor of Neurology, Psychiatry, Psychology, and Neuroscience, University of Iowa Carver College of Medicine, Iowa City, IA Principal Investigator, PREDICT-HD, Study of Early Markers in HD Adam Rosenblatt, M.D. Director, HDSA Center of Excellence at Johns Hopkins, Baltimore Maryland Associate Professor of Psychiatry, and Director of Neuropsychiatry, Johns Hopkins University School of Medicine Vicki Wheelock, M.D. Director, HDSA Center of Excellence at University of California Clinical Professor, Neurology, University of California, Davis Medical Center, Sacramento, CA Site Investigator, Huntington Study Group Editors: Debra Lovecky Director of Programs, Services & Advocacy, HDSA Karen Tarapata Designer: J&R Graphics Printed with funding from an educational grant provided by 1 Disclaimer The indications and dosages of drugs in this book have either been recommended in the medical literature or conform to the practices of physicians’ expert in the care of people with Huntington’s Disease.
    [Show full text]
  • Histamine Receptor
    Histamine Receptor Histamine Receptors are a class of G protein-coupled receptors with histamine as their endogenous ligand. There are four known histamine receptors: H1 receptor, H2 receptor, H3 receptor, H4 receptor. The H1 receptor is a histamine receptor belonging to the family of Rhodopsin-like G-protein-coupled receptors. This receptor, which is activated by the biogenic amine histamine, is expressed throughout the body, to be specific, in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. H2 receptors are positively coupled to adenylate cyclase via Gs. It is a potent stimulant of cAMP production, which leads to activation of Protein Kinase A. Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act asautoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The Histamine H4 receptor has been shown to be involved in mediating eosinophil shape change and mast cell chemotaxis. www.MedChemExpress.com 1 Histamine Receptor Inhibitors & Modulators (±)-Methotrimeprazine (D6) (±)-Tazifylline (dl-Methotrimeprazine D6) Cat. No.: HY-19489S Cat. No.: HY-U00018 Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Bioactivity: (±)-Tazifylline is a potent, selective and long-acting Methotrimeprazine, which is a D3 dopamine and Histamine H1 histamine H1 receptor antagonist. receptor antagonist. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg, 5 mg, 10 mg, 20 mg ABT-239 Acrivastine Cat. No.: HY-12195 (BW825C) Cat. No.: HY-B1510 Bioactivity: ABT-239 is a novel, highly efficacious, Bioactivity: Acrivastine (BW825C) is a short acting histamine 1 non-imidazole class of H3R antagonist and a transient receptor antagonist for the treatment of allergic rhinitis.
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]